BioCentury
ARTICLE | Distillery Therapeutics

Musculoskeletal

November 30, 2016 2:08 PM UTC

Patient sample and rabbit studies suggest sclerostin or other inhibitors of canonical WNT signaling could help treat joint injury. In fibrocartilage samples from 12 patients undergoing temporomandibul...

BCIQ Company Profiles

Columbia University

BCIQ Target Profiles

Sclerostin